Loading...
XNYS
ZTS
Market cap30bUSD
Oct 08, Last price  
73.08USD
1D
2.14%
1Q
-3.28%
Jan 2017
36.52%
IPO
135.59%
Name

Zoetis Inc

Chart & performance

D1W1MN
XNYS:ZTS chart
P/E
11.46
P/S
3.24
EPS
6.38
Div yield, %
2.74%
Shrs. gr., 5y
-1.50%
Rev. gr., 5y
7.24%
Revenues
9.47b
+2.28%
2,760,000,0003,582,000,0004,233,000,0004,336,000,0004,561,000,0004,785,000,0004,765,000,0004,888,000,0005,307,000,0005,825,000,0006,260,000,0006,675,000,0007,776,000,0008,080,000,0008,544,000,0009,256,000,0009,467,000,000
Net income
2.67b
+7.52%
-100,000,000110,000,000245,000,000436,000,000504,000,000583,000,000339,000,000821,000,000864,000,0001,428,000,0001,500,000,0001,638,000,0002,037,000,0002,114,000,0002,344,000,0002,486,000,0002,673,000,000
CFO
2.90b
-1.66%
98,000,000254,000,000497,000,000454,000,000681,000,000626,000,000664,000,000713,000,0001,346,000,0001,790,000,0001,795,000,0002,126,000,0002,213,000,0001,912,000,0002,353,000,0002,953,000,0002,904,000,000
Dividend
Jul 20, 20260.53 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zoetis Inc. is a global enterprise dedicated to the research, development, production, and marketing of a broad spectrum of animal health products. Operating both within the United States and globally, the company primarily serves a diverse range of animals, including major livestock categories such as cattle, swine, poultry, fish, and sheep, alongside companion animals like dogs, cats, and horses. Their extensive portfolio features various solutions, including biological vaccines engineered to prevent ailments of the respiratory, gastrointestinal, and reproductive systems, or to stimulate targeted immune responses. They also provide anti-infectives designed to combat bacterial, fungal, or protozoal pathogens, and parasiticides effective against both internal (e.g., worms) and external (e.g., fleas, ticks) parasites. Beyond these, Zoetis offers a suite of other pharmaceutical products, spanning pain management, sedation, antiemetics, reproductive aids, and oncology treatments. Their offerings also include dermatological solutions for allergic skin conditions and atopic dermatitis, as well as medicated feed additives specifically for livestock. The company further innovates in diagnostic tools, offering portable blood and urine analysis systems, point-of-care devices, instruments, reagents, rapid immunoassay tests, reference laboratory services, and blood glucose monitors. Non-pharmaceutical lines extend to nutritional supplements, agribusiness support, biodevices, genetic testing, and precision animal health technologies. Zoetis reaches its customer base, which comprises veterinarians, livestock producers, and retail outlets, through its own sales representatives and specialized technical and veterinary operations personnel, as well as via third-party veterinary distributors. Founded in 1952, the firm maintains its headquarters in Parsippany, New Jersey.

Related entities

Subsidiaries (12)
PHARMAQ AS
PHARMAQ VIETNAM CO., LTD
ZOETIS BELGIUM
ZOETIS BIOPHARMACEUTICAL CO., LTD.
Zoetis Ceska republika, s.r.o.
Zoetis India Capability Center Private Limited
ZOETIS KOREA LTD
ZOETIS PHARMACEUTICAL RESEARCH PRIVATE LIMITED
ZOETIS PHILIPPINES, INC.
ZOETIS SINGAPORE PTE. LTD.
ZOETIS TREASURY CENTER
ZOETIS VIETNAM CO., LTD

Key people

Non-Executive Independent Chairman of the Board · since 2015
Glenn C. David
Chief Financial Officer, Executive Vice President · since 2016
Catherine A. Knupp
Executive Vice President, President - Research and Development · since 2012
Roman Trawicki
Executive Vice President, President - Global Manufacturing and Supply · since 2015
Heidi C. Chen
Executive Vice President, General Counsel, Corporate Secretary · since 2012
Independent Director · since 2015
Independent Director · since 2016
Sanjay Khosla
Independent Director · since 2013
Independent Director · since 2013
Louise M. Parent
Independent Director · since 2013
Willie M. Reed
Independent Director · since 2014
Linda Rhodes
Independent Director · since 2017
Independent Director · since 2013
IPO date
Feb 01, 2013
Employees
13,800
Domiciled in
US
Incorporated in
US
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
10 Sylvan Way
Parsippany-Troy Hills, NJ 07054
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT